Cann Group Limited (ASX: CAN) reported a pivotal year marked by substantial operational, financial, and strategic advancements, positioning the company for sustainable profitability in FY26. Dried flower output increased 35% year-on-year to 5.9 tonnes, supported by improved yields, efficiency gains, and cost reductions that lowered operating expenses by 35%. Revenue momentum is being driven by the Botanitech flower range, bulk flower sales, and expanded branded product categories including oils, vapes, and gummies.
A major recapitalisation delivered an 81% reduction in core debt, lowering it to AU$14.5m and significantly strengthening the balance sheet while reducing interest burdens. The state-of-the-art Mildura GMP facility is operating at scale, enabling consistent supply, stronger margins, and entry into export markets such as the UK and Poland. With FY26 revenue forecast to grow ~50% to approximately AU$17m, Cann is targeting EBITDA of AU$0.3m–AU$0.7m, underpinned by rising demand for Australian-grown medicinal cannabis and disciplined cost management.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au.au.au
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Cann Group Limited AGM Presentation Summary
Cann Group Limited (ASX: CAN) reported a pivotal year marked by substantial operational, financial, and strategic advancements, positioning the company for sustainable profitability in FY26. Dried flower output increased 35% year-on-year to 5.9 tonnes, supported by improved yields, efficiency gains, and cost reductions that lowered operating expenses by 35%. Revenue momentum is being driven by the Botanitech flower range, bulk flower sales, and expanded branded product categories including oils, vapes, and gummies.
A major recapitalisation delivered an 81% reduction in core debt, lowering it to AU$14.5m and significantly strengthening the balance sheet while reducing interest burdens. The state-of-the-art Mildura GMP facility is operating at scale, enabling consistent supply, stronger margins, and entry into export markets such as the UK and Poland. With FY26 revenue forecast to grow ~50% to approximately AU$17m, Cann is targeting EBITDA of AU$0.3m–AU$0.7m, underpinned by rising demand for Australian-grown medicinal cannabis and disciplined cost management.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au.au.au